A meta-analysis showed that hypoglycemic medicine glucagon-like peptide 1 receptor agonists (GLP-1RA) reduced the risk of kidney disease progression by 18% (hazard ratio (HR), 0.82, 95% confidence interval (CI): 0.75-0.89, P<0.001), while sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the mentioned risk by 38% (HR, 0.62, 95%CI, 0.58-0.67, P<0.001) (15). The gene discussed is SLC5A2; the disease is kidney disorder.